ZIOP - ジオファ―ム・オンコロジ― (ZIOPHARM Oncology Inc) ジオファ―ム・オンコロジ―

 ZIOPのチャート


 ZIOPの企業情報

symbol ZIOP
会社名 ZIOPHARM Oncology Inc (ジオファ―ム・オンコロジ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジオファーム・オンコロジー(ZIOPHARM Oncology Inc.)は医療ニーズに対応する癌治療のポートフォリオを独自に、またはパートナーと共に開発、獲得、および商業化しようとするバイオ医薬品企業である。同社はがんおよび移植片対宿主病の治療のための細胞およびウイルスに基づく治療法を提供するために、遺伝子発現、制御および細胞技術を使用する免疫腫瘍学における製品の開発に焦点を当てている。同社はレオスイッチ治療システム(RTS)発現プラットフォームの制御下で腫瘍内に投与されるアデノウイルスベクターAd-RTS-IL-12を開発した。免疫腫瘍プラットフォームを使用して開発される初期の臨床段階の製品候補はAd-RTS-IL-12 + veledimexである。Ad-RTS-IL-12 + veledimexはインターロイキン12を産生するためにその遺伝子送達系を使用する。   ジオファ―ム・オンコロジ―は、米国のバイオ医薬品メ―カ―。独自の小分子薬剤候補と合成生物学のプラットフォ―ムの開発・ライセンス供与を通じ、がん剤の開発、商品化に注力する。同社の小分子薬剤候補は、「palifosfamide」「indibulin」「darinaparsin」などがあり、静脈内または経口より投与する。   Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
本社所在地 One First Avenue Parris Building 34 Navy Yard Plaza Boston MA 02129 USA
代表者氏名 Laurence James Neil Cooper ローレンス・ジェームス・ニール・クーパー
代表者役職名 Chief Executive Officer
電話番号 +1 617-259-1970
設立年月日 36039
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数
url www.ziopharm.com
nasdaq_url https://www.nasdaq.com/symbol/ziop
adr_tso
EBITDA EBITDA(百万ドル) -54.63100
終値(lastsale) 2.85
時価総額(marketcap) 405782344.5
時価総額 時価総額(百万ドル) 378.73020
売上高 売上高(百万ドル) 3.34100
企業価値(EV) 企業価値(EV)(百万ドル) 492.75420
当期純利益 当期純利益(百万ドル) -74.50900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ZIOPHARM Oncology Inc. revenues decreased 95% to $146K. Net loss applicable to common stockholders increased 3% to $38.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other General and Administrative increase of 55% to $6.9M (expense) Stock-based Compensation in SGA increase of 42% to $4.2M (expense).

 ZIOPのテクニカル分析


 ZIOPのニュース

   Global Immunotherapy Markets, 2021-2027: Growth Drivers Include Increasing Prevalence of Auto-Immune Diseases in Adults and Increasing Investments in Research and Funding of Cancer - ResearchAndMarkets.com  2022/02/02 14:35:00 Kwhen Finance
   ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Expected to Post Earnings of -$0.09 Per Share  2021/12/19 14:18:45 Dakota Financial News
Equities analysts expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to report earnings of ($0.09) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ZIOPHARM Oncologys earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.11). ZIOPHARM Oncology reported earnings of ($0.11) per share during the same []
   Zacks: Brokerages Expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to Announce -$0.09 EPS  2021/12/07 00:40:43 Dakota Financial News
Brokerages expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to announce earnings of ($0.09) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for ZIOPHARM Oncology’s earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.07). ZIOPHARM Oncology reported earnings of ($0.11) per share in […]
   Gateway Advisory LLC Buys Shares of 15,301 ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)  2021/12/06 14:50:46 Transcript Daily
Gateway Advisory LLC bought a new stake in ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,301 shares of the biotechnology companys stock, valued at approximately $28,000. Other large investors also recently added []
   Stock on the Move: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Orchid Island Capital, Inc. (NYSE:ORC)  2021/12/06 08:22:13 Stock Equity
ZIOPHARM Oncology, Inc. (ZIOP) with the stream of -7.58% also noticed, India Orchid Island Capital, Inc. (ORC) encountered a rapid change of -2.25% in the last hour of trading session. The post Stock on the Move: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Orchid Island Capital, Inc. (NYSE:ORC) appeared first on Stocks Equity .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジオファ―ム・オンコロジ― ZIOP ZIOPHARM Oncology Inc)

 twitter  (公式ツイッターやCEOツイッターなど)